article Open AccessTop 1% cited
Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir
British Journal of Clinical Pharmacology · 1997 · Vol. 44(2) · pp. 190–194
Victoria A. Eagling✉(University of Liverpool)David Back(University of Liverpool)Michael Barry(University of Liverpool)
Abstract
The HIV protease inhibitors have differential effects on CYP isozymes. There is obvious potential for clinically significant drug interactions particularly with ritonavir. Pharmacokinetic drug interaction studies are crucial to gain an overall understanding of the beneficial and potentially harmful effects of this important group of drugs.
HIV/AIDS drug development and treatmentPharmacogenetics and Drug MetabolismPharmacological Effects and Toxicity StudiesIndinavirChlorzoxazoneTolbutamideSaquinavirRitonavirPhenacetinChemistryCYP1A2CYP3A4Pharmacology
MeSH terms
AdolescentAdultChildFemaleHumansIsoenzymesLiverMaleHIV Protease InhibitorsSaquinavirRitonavirIndinavirCytochrome P-450 Enzyme InhibitorsIn Vitro Techniques
Citations
335
FWCI
13.03
field-weighted impact
References
0
Percentile
99%
vs. same field & year
Citations per year
Related articles
Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir
British Journal of Clinical Pharmacology · 1997 · 335 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.